Trimetrexate

Trimetrexate

SCHEMBL7108746

COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C(O)C(F)(F)F

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 9/20 0.81
MEN1 O00255 1/20 0.81
ALDH1A1 P00352 1/20 0.81
ESR1 P03372 1/20 0.81
CHRM2 P08172 1/20 0.81
HTR1A P08908 1/20 0.81
MAPT P10636 1/20 0.81
CHRM1 P11229 1/20 0.81
HPGD P15428 1/20 0.81
MAOA P21397 1/20 0.81
DRD1 P21728 1/20 0.81
ACHE P22303 1/20 0.81
PTGS1 P23219 1/20 0.81
SLC6A2 P23975 1/20 0.81
PDE4A P27815 1/20 0.81
OPRM1 P35372 1/20 0.81
DRD3 P35462 1/20 0.81
BLM P54132 1/20 0.81
SLC6A3 Q01959 1/20 0.81
KMT2A Q03164 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimetrexate SCHEMBL7099424 0.92 DHFR (0.88) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL7099127 0.92 DHFR (0.86) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL29376841 0.90 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL3983 0.90 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL29403928 0.90 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL10701228 0.90 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL7099831 0.89 DHFR (0.98) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL29906169 0.89 DHFR (0.98) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL7099341 0.89 DHFR (0.98) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL8588679 0.89 DHFR (0.81) DHFRMEN1ALDH1A1ESR1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216418-A1 Novel compositions comprising trimetrexate and methods of their synthesis and use MEDIMMUNE ONCOLOGY, INC. 2003-11-20 US disclosed
US-6576635-B2 Trimetrexate ascorbate and compositions comprising trimetrexate and ascorbic acid useful as anticarcinogenic agents, bactericides, antiprotozoa agents and antidiabetic agents; heat, light, oxygen and water resistant MEDIMMUNE ONCOLOGY, INC. 2003-06-10 US disclosed
US-20010031755-A1 Novel compositions comprising trimetrexate MEDIMMUNE ONCOLOGY, INC. 2001-10-18 US disclosed
US-6258821-B1 TRIMETREXATE ASCORBATE DIHYDROFOLATE REDUCTASE ACTIVITY COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOSITION VIRAL INFECTION, FUNGAL INFECTION, YEAST INFECTION, BACTERIA MEDIMMUNE ONCOLOGY, INC. 2001-07-10 US disclosed
WO-2000064447-A1 NOVEL COMPOSITIONS COMPRISING TRIMETREXATE AND METHODS OF THEIR SYNTHESIS AND USE MEDIMMUNE ONCOLOGY, INC. (US) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031755-A1 Novel compositions comprising trimetrexate MTHFD1, TYMS, DHFR DHFR 3/4885MEN1 3280/4885ALDH1A1 1886/4885
US-20030216418-A1 Novel compositions comprising trimetrexate and methods of their synthesis and use TYMS, MTHFD1, DHFR DHFR 3/4885MEN1 3211/4885ALDH1A1 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.